



STAMFORD
PHARMACEUTICALS INC

Stamford Pharmaceuticals announced receiving HREC approval for the commencement of the initial phase of its registration program

August 6th 2019

Stamford Pharmaceuticals announced today receiving ethics approval for the Pilot phase of its registration program. The program will commence initially at Australian sites with US sites for the program planned for initiation in 2020. The Pilot phase of the registration program will evaluate clearance of basal cell carcinomas in patients with multiple BCCs using the SP-002 (formerly known as ASN-002) monotherapy as well as in combination with a small molecule chemotherapy. This program will also further inform study design and optimize the timing for critical endpoint evaluation. Results will inform and ascertain the design aspects of the Confirmatory phase of clinical development. The initial Australian site for the study will be Central Brisbane Dermatology Center led by Associate Professor Greg Siller as the Principal Investigator. Dr Siller has had extensive experience in the clinical development of several agents that have been approved for non-melanoma skin cancers and was a Principal Investigator on an earlier Phase 1-2 study involving the current product.

-END-

About Stamford pharmaceuticals

Stamford pharmaceuticals is clinical stage immunology and inflammation focused company developing rational combination therapies that aim to improve patient lives. Cancers are complex dynamic and adaptive diseases where the tumor micro-environment comprises many different cell types, matrix proteins and secreted molecules. These elements form a highly redundant regulatory network that enables continued tumor survival, adaptation and progression even in the face of potent treatments. There is clear evidence that single-target drugs do not provide durable outcomes for many patients. We believe that taking a network multi-target approach offer a better opportunity to improving response rates and durability by maximizing synergistic efficacy while reducing off-target toxicities.



STAMFORD
PHARMACEUTICALS INC

Please visit stamfordpharmaceuticals.com

Company Contact:

Clement Leong

Stamford Pharmaceuticals,

CEO

E: clementleong@stamfordpharma.com

Investor Relations Contact:

The Ruth Group

T: 646 536 7035

E: tbui@theruthgroup.com